Trospium chloride | 10405-02-4 | muscarinic antagonist

MedKoo Cat#: 318960 | Name: Trospium chloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Trospium chloride is a muscarinic antagonist. Trospium chloride antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs including the bladder. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder. Receptor assays showed that trospium chloride has negligible affinity for nicotinic receptors as compared to muscarinic receptors at concentrations obtained from therapeutic doses.

Chemical Structure

Trospium chloride

CAS#10405-02-4 (chloride)

Theoretical Analysis

MedKoo Cat#: 318960

Name: Trospium chloride

CAS#: 10405-02-4 (chloride)

Chemical Formula: C25H30ClNO3

Exact Mass: 0.0000

Molecular Weight: 427.97

Elemental Analysis: C, 70.16; H, 7.07; Cl, 8.28; N, 3.27; O, 11.22

Price and Availability

Size	Price	Availability
1g	USD 350.00	2 Weeks
500mg	USD 550.00	2 Weeks
2g	USD 750.00	2 Weeks
5g	USD 1,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

10405-02-4 (chloride) 47608-32-2 (cation) 1050405-50-9 (iodide) 1006028-67-6 (bromide) 1006028-56-3 (acetate)

Synonym

IP631; IP-631; IP 631; Trospium chloride, Relaspium;

IUPAC/Chemical Name

(1R,3s,5S)-3-(2-hydroxy-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,1'-pyrrolidin]-8-ium chloride

InChi Key

RVCSYOQWLPPAOA-HLUKFBSCSA-M

InChi Code

InChI=1S/C25H30NO3.ClH/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26;/h1-6,9-12,21-23,28H,7-8,13-18H2;1H/q+1;/p-1/t21-,22-;/m1./s1

SMILES Code

O=C(C(C1=CC=CC=C1)(O)C2=CC=CC=C2)O[C@@H]3C[C@H]([N+]45CCCC4)CC[C@H]5C3.[Cl-]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 427.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Luca M, Luca A, Serretti A. A Clinically Oriented Review of New Antipsychotics for Schizophrenia. Neuropsychiatr Dis Treat. 2024 Dec 27;20:2637-2649. doi: 10.2147/NDT.S501560. PMID: 39741904; PMCID: PMC11687306. 2: Fabiano N, Wong S, Zhou C, Correll CU, Højlund M, Solmi M. Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2024 Dec 25;92:62-73. doi: 10.1016/j.euroneuro.2024.11.013. Epub ahead of print. PMID: 39724748. 3: Syed YY. Xanomeline/Trospium Chloride: First Approval. Drugs. 2024 Dec 24. doi: 10.1007/s40265-024-02126-0. Epub ahead of print. PMID: 39715912. 4: Horan WP, Sauder C, Harvey PD, Ramsay IS, Yohn SE, Keefe RSE, Davis VG, Paul SM, Brannan SK. The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials. Am J Psychiatry. 2024 Dec 11. doi: 10.1176/appi.ajp.20240076. Epub ahead of print. PMID: 39659157. 5: Furqan M. Redefining schizophrenia treatment with muscarinic modulation-A perspective. Eur Neuropsychopharmacol. 2024 Dec 5;92:19-20. doi: 10.1016/j.euroneuro.2024.11.014. Epub ahead of print. PMID: 39642767. 6: Menegaz de Almeida A, Moraes Tamashiro F, Cavalcanti Souza ME, Luiz Silvério II, de Almeida Souza Miranda C, Barros Andrade Í, Kreuz M, Aquino de Moraes FC, Kelly FA. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: A systematic review and meta-analysis. J Psychiatr Res. 2024 Nov 28;181:262-272. doi: 10.1016/j.jpsychires.2024.11.047. Epub ahead of print. PMID: 39637717. 7: Iyen B, Coupland C, Bell BG, Ashcroft DM, Orrell MW, Bishara D, Dening T, Avery AJ. Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control study. BMJ Med. 2024 Nov 12;3(1):e000799. doi: 10.1136/bmjmed-2023-000799. PMID: 39574420; PMCID: PMC11580265. 8: Hasan AH, Abid MA. Cobenfy (Xanomeline-Trospium Chloride): A New Frontier in Schizophrenia Management. Cureus. 2024 Oct 9;16(10):e71131. doi: 10.7759/cureus.71131. PMID: 39525169; PMCID: PMC11548987. 9: Kaul I, Sawchak S, Claxton A, Sauder C, Hassman HH, Kakar R, Walling DP, Citrome L, Zhu H, Miller AC, Brannan SK. Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double- blind, placebo-controlled, EMERGENT trials. Schizophrenia (Heidelb). 2024 Nov 2;10(1):102. doi: 10.1038/s41537-024-00525-6. PMID: 39488504; PMCID: PMC11531488. 10: Hajebrahimi S, Pourmohammad A, Konstantinidis C, Samarinas M, Morsali S, Mostafaei H, Farhoudi M, Rahnama'i MS, Beheshti R, Salehi-Pourmehr H. Safety and Efficacy of Trospium Chloride and Solifenacin in Stroke-Induced Neurogenic Lower Urinary Tract Dysfunction: A Randomized Controlled Trial. Neurourol Urodyn. 2025 Jan;44(1):85-95. doi: 10.1002/nau.25614. Epub 2024 Oct 29. PMID: 39469916. 11: Beninger P. Xanomeline and Trospium Chloride. Clin Ther. 2024 Nov;46(11):938-939. doi: 10.1016/j.clinthera.2024.10.001. Epub 2024 Oct 22. PMID: 39443264. 12: Komatsu Y, Takehara M, Hart X, Takahashi Y, Hori S, Ueno F, Uchida H. Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments. Pharmacopsychiatry. 2024 Sep;57(5):221-231. doi: 10.1055/a-2307-6484. Epub 2024 May 6. PMID: 38710208. 13: Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2024 Aug 1;81(8):749-756. doi: 10.1001/jamapsychiatry.2024.0785. Erratum in: JAMA Psychiatry. 2024 Aug 1;81(8):846. doi: 10.1001/jamapsychiatry.2024.2002. PMID: 38691387; PMCID: PMC11063924. 14: Fisher SR, Villasante-Tezanos A, Allen LM, Pappadis MR, Kilic G. Comparative effectiveness of pelvic floor muscle training, mirabegron, and trospium among older women with urgency urinary incontinence and high fall risk: a feasibility randomized clinical study. Pilot Feasibility Stud. 2024 Jan 4;10(1):1. doi: 10.1186/s40814-023-01440-w. PMID: 38178267; PMCID: PMC10765875. 15: Farghaly TA, Masaret GS, Abdulwahab HG. The patent review of the biological activity of tropane containing compounds. Expert Opin Ther Pat. 2023 Dec;33(12):875-899. doi: 10.1080/13543776.2023.2299349. Epub 2024 Jan 15. PMID: 38165255. 16: Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024 Jan 13;403(10422):160-170. doi: 10.1016/S0140-6736(23)02190-6. Epub 2023 Dec 14. Erratum in: Lancet. 2024 Jun 1;403(10442):2380. doi: 10.1016/S0140-6736(24)01041-9. PMID: 38104575. 17: Kulchavenya EV, Shevchenko SY. [Impact of the SARS-CV-2 virus on the urinary bladder]. Urologiia. 2023 Mar;(1):41-45. Russian. PMID: 37401682. 18: Bhide AA, Digesu GA, Swift S. Overactive bladder medication - do we need to revisit trospium chloride for our elderly patients? Int Urogynecol J. 2023 May;34(5):961-962. doi: 10.1007/s00192-023-05559-5. Epub 2023 Apr 26. PMID: 37099160. 19: Korshunova ES, Andreev MN, Korshunov MN, Pyatnitskaya TM, Korshunov DM, Darenkov SP, Suponeva NA. [Long-term safety and efficacy of trospium chloride for the treatment of neurogenic overactive bladder due to Parkinson's disease is there an effect on cognitive status?]. Urologiia. 2022 Dec;(6):71-77. Russian. PMID: 36625617. 20: Yosrey E, Elmansi H, Sheribah ZA, Metwally ME. Novel approaches of erythrosine B as a food dye-derived spectroscopic probe for assessing trospium chloride in raw material and dosage form. Luminescence. 2022 Oct;37(10):1785-1792. doi: 10.1002/bio.4358. Epub 2022 Aug 16. PMID: 35922904.